Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
CALGB 10403
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- NCT00558519 ↗
- Completed
- Alliance for Clinical Trials in Oncology
- Deep
We haven't built an HCP commentary report on CALGB 10403 (daunorubicin hydrochloride, doxorubicin hydrochloride and 8 more in Leukemia) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CALGB 10403 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 115 | |
| YouTube | 19 | |
| Podcasts | 12 | |
| Bluesky threads | 11 |
The trial
ClinicalTrials.gov- Official title
- An Intergroup Phase II Clinical Trial for Adolescents and Young Adults With Untreated Acute Lymphoblastic Leukemia (ALL)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Leukemia
- Interventions
- cyclophosphamide; cytarabine; daunorubicin hydrochloride; dexamethasone; doxorubicin hydrochloride; mercaptopurine; methotrexate; pegaspargase; thioguanine; vincristine sulfate; radiation therapy
- Arms
- Treatment (chemotherapy, radiotherapy) · Experimental
- Enrollment
- 318
- Primary outcomes
- Complete Response Rate
- Event-free Survival
- Disease-free Survival
- Overall Survival
- Number of Participants Who Experienced at Least One Grade 3 or Higher Adverse Event at Least Possibly Related to Treatment (Toxicity)
- Sponsor
- Alliance for Clinical Trials in Oncology with National Cancer Institute (NCI)
- Start
- Mar 12, 2008
- Primary completion
- Sep 2016
- Results posted
- Yes
- Registry record
- NCT00558519 · updated Apr 29, 2026
Publications
linked from the registry- Bleyer A: Older adolescents and young adults with acute lymphoblastic leukemia (ALL) in the United States: from the lowest to highest death rate and number of deaths--more rationale for the CALBG-SWOG-ECOG C10403 trial based on COG AALL0232. [Abstract] J Clin Oncol 26 (Suppl 15): A-18034, 2008.
- Advani AS, Larsen E, Laumann K, Luger SM, Liedtke M, Devidas M, Chen Z, Yin J, Foster MC, Claxton D, Coffan K, Tallman MS, Appelbaum FR, Erba H, Stone RM, Hunger SP, McNeer JL, Loh ML, Raetz E, Winick N, Carroll W, Larson RA, Stock W. Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. Blood Adv. 2021 Jan 26;5(2):504-512. doi: 10.1182/bloodadvances.2020002439. PubMed 33496745
- Stock W, Luger SM, Advani AS, Yin J, Harvey RC, Mullighan CG, Willman CL, Fulton N, Laumann KM, Malnassy G, Paietta E, Parker E, Geyer S, Mrozek K, Bloomfield CD, Sanford B, Marcucci G, Liedtke M, Claxton DF, Foster MC, Bogart JA, Grecula JC, Appelbaum FR, Erba H, Litzow MR, Tallman MS, Stone RM, Larson RA. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019 Apr 4;133(14):1548-1559. doi: 10.1182/blood-2018-10-881961. Epub 2019 Jan 18. PubMed 30658992